

MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee
Woolfolk Building
Conference Center East, Room 145
Jackson, MS 39201-1399
August 13, 2019
9:00am to 5:00pm

AGENDA

- I. Call to Order
- II. Welcome & Introductions
- III. Administrative Matters
- IV. Approval of May 7, 2019 Meeting Minutes
- V. PDL Compliance/Generic Percent Report Updates
- VI. Drug Class Announcements
- VII. Public Comment
- VIII. New Drug/New Generic Reviews
 - a. Analgesics, Narcotic, Short Acting-Apadaz (Benzhydrocodone/APAP)
 - b. Anticonvulsants, Adjuvants- Diacomit (Stiripentol)
 - c. Antineoplastics, Select Enzyme Inhibitors- Balversa (erdafitinib)
 - d. Antiretrovirals, Single Tablet Regimens-Dovato (dolutegravir-lamivudine)
 - e. Bone Resorption Suppression & Related Agents- Evenity (romosozumab-aqqg)
 - f. Cytokine & CAM Antagonists- Skyrizi (risankizumab-rzaa)
 - g. Immune Globulins
 - 1. Cablivi (caplacizumab-yhdp)
 - 2. Cutaquig (immune globulin- hipp)
 - h. Multiple Sclerosis Agents, Oral
 - 1. Mavenclad (cladribine)
 - 2. Mayzent (siponimod)
 - i. NSAIDS, COX II Selective- Qmiiz ODT (meloxicam) financial review
 - j. Ophthalmic, Glaucoma Agents- Rocklatan (netarsudil-latanoprost)
 - k. Steroids (Topical), Very High Potency
 - 1. Duobrii (halobetasol/tazarotene)
 - 2. Lexette (halobetasol propionate) financial review
 - l. Tetracyclines- Seysara (sarecycline)
- IX. Division of Medicaid Update
- X. Next Meeting Date- Tuesday, October 22, 2019
- XI. Adjournment